Novartis Sues Sun Over Proposed Generic Zometa, Reclast
Sun, based in Mumbai, has sought U.S. Food and Drug Administration approval to sell copies, according to a complaint filed July 14 in federal court in Newark, New Jersey. Novartis claims the Sun drugs would infringe its patent, which expires in 2028. Basel-based Novartis requested a court order to block the generic drugs until then.
Novartis reported Zometa sales of $1.49 billion last year and Reclast sales of $613 million.
Uday Baldota and Mira Desai, representatives of Sun, didn’t immediately respond to an e-mail seeking comment on the lawsuit outside regular business hours in India.
The case is Novartis v. Sun Pharmaceuticals, 12-cv-4393, U.S. District Court, District of New Jersey (Newark).
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.